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Summary Cumulative toxicity is a well known limitation of antipsoriatic treatments. In particular, the
induction of multiple squamous cell carcinomas following long-term PUVA treatment is well 
established. In the present report, a psoriatic patient is described who was treated for more than 
14 years with photochemotherapy (PUVA) and who received excessive amounts of topical cortico­
steroids. The patient developed, in total, 34 squamous cell carcinomas. In all, three squamous cell 
carcinomas developed during long-term PUVA treatment, and 21 carcinomas appeared during 16 
months of treatment with cyclosporin. Subsequently, a marked inhibition of the occurrence of new 
tumours occurred during prolonged treatment with acitretin, and no new tumours have appeared 
during the last 4 years of continuous treatment with this retinoid at a dose of 60 mg/day.
Modulation of the expression of PUVA-induced squamous cell carcinomas by cyclosporin and 
acitretin are discussed. The present report lends support to the hypothesis that cyclosporin causes an 
increased occurrence of PUVA-induced carcinomas, whereas acitretin (60mg/day) is of value in 
preventing the occurrence of new squamous cell carcinomas in patients who were treated with long­
term PUVA.
Several studies have demonstrated that prolonged 
photochemotherapy (PUVA) is associated with an 
increased occurrence of squamous cell carcinomas.1-4 
Deaths due to metastasizing squamous cell carcinomas 
due to excessive PUVA treatment have occurred.5 Cyclo­
sporin treatment also has been reported to be associated 
with an increased occurrence of squamous cell carci­
nomas.6~7 In particular, the combination of both treat­
ments may increase the cancer risk substantially.
modulation of the occurrence of PUVA-induced card 
nomas by cyclosporin and acitretin is discussed.
Case report
A 5 9-year-old man suffered from extensive recalcitrant 
psoriasis for more than 40 years. At times the psoriatic 
lesions became erythrodermic. The patient had been




history of radiotherapy treatment nor of arsenic inges­
tion. From 1975 onwards, the patient was treated with 
more than 2500 PUVA exposures, in total. The treat­
ment schedule was four times per week, without inter-
Systemic treatment with 1 3-ds-retinoic acid, 
tinate and acitretin have reduced the occurrence of 
non-melanoma skin cancers in cancer-prone conditions 
such as the basal cell naevus syndrome, xeroderma 
pigmentosum, renal transplantation and sun-damaged 
skin.10
In this report, a patient is described who was treated 
for 14 years with photochemotherapy, resulting in three 
squamous cell carcinomas. During 16 months treat­
ment with cyclosporin, 21 squamous cell carcinomas 
appeared.11 Subsequently, treatment with acitretin 
(60 mg/day) for 6 years, resulted in a decreased occur- three squamous cell carcinomas 
rence of new tumours (in the first 2 years) and the tion, with topical ' *1




y years. PUVA treatment was discontinued 
patient developed numerous lentigines and 
i . Etretinate, in combina- 
corticosteroids, and methotrexate, in
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in A was t at a dose of 10 mg/kg per
day. Al that time, no squamous cell carcinomas were 
present. However, numerous lentigines and multiple 
striae were observed. The severe extent of the psoriatic 
lesions necessitated systemic treatment. At first, this 
treatment proved to be effective. However, a severe 
relapse occurred at a dose of 5 mg/kg per day. After 
initiation of cyclosporin treatment, new squamous cell 
carcinomas continued to appear. During 16 months of 
treatment with cyclosporin, 21 squamous cell carcino- 
masa had appeared (one on the lower lip, three on the 
arms and 17 on the legs).11 In this stage, the patient 
was referred to our centre for further treatment.
The patient was admitted for 7 months. Severe ery-
was present. The hair was sparse, and 
extensive psoriatic nail changes were observed. At the 
flexures, multiple striae were observed. On the legs and 
presternal areas, multiple hyperkeratotic papules were 
present. A thoracic kyphosis was evident. Both eyes 
showed cataracts. Blood investigations revealed a corti­
sone level of 0-07^.mol/l (normal range 0-19- 
0 5 5  /miol/1). X-ray examination of the vertebral 
column revealed severe osteoporotic changes with 
block vertebra at C6 and C7, and compression of several 
thoracic vertebra.
Treatment with cyclosporin and topical corticoster­
oids was discontinued. At the erythrodermic stage,
5 mg/day, was instituted, and topical treat­
ments consisted of crude coal tar ( 3-5% in zinc paste or 
petrolatum-lanette), chrysarobin ointment (up to 3%), 
;t-contuct dithranol ((M)5-l%) and 2 4 h appli­
cations of dithranol in lanette cream and Optidenn
ointment (Hermal, Hamburg, Germany). After 3 
months of treatment as an in-patient, the lesions had 
improved considerably, and a better inspection of the 
hyperkeratotic lesions was possible. In this stage, the 
dose of acitretin was increased to 50 mg/day.
Following resolution of the psoriatic lesions, exami­
nation of the skin revealed numerous lentigi 
circumscribed hyperkeratoses predominantly on 
legs, presternal area and arms (Fig. 1). Some of
md others were ulcerated 
(Fig. 2). The histopathological appearance was of well- 
differentiated squamous cell carcinomas (Fig. 3). Up to 
January 1992, 13 squamous cell carcinomas and four 
PUVA keratoses were excised from the legs, and four 
keratoses were removed from the trunk and arms. Areas 
with multiple and small sized hyperkeratotic 
were treated with 5-iluorouracil cream.
After 7 months of treatment, the extent and severity 




PUVA keratoses and squamous cell carcinomas on
as an out-patient. From September 1990 
onwards, the dose of acitretin was between 50 and 
70 mg/day. From January 1992 to the present (June 
1996) no new PUVA keratoses or squamous cell carci­
nomas have appeared. During these years, the severity 
of the psoriatic lesions was limited to some plaques,
be managed with topical treatments suchc
as cî ointment and tar preparations.
Two months after discontinuation of topical cortico-
serum cor wassteroids and
0-28 jumol/I. In order to compensate for the adrenal 
gland insufficiency, cortisone acetate, 37-5 ing/day, was
administered. During the subsequent 18
of
{()• 30 itmol/l) and
cor to normal
level of adrenocorticoti
hormone also was normal (4-7 pmol/1). In 1990, extra- 
capsular cataract extraction and lens implantation were 
performed. An X-ray examination and skeletal deriso- 
metry revealed severe signs of osteoporosis. For this
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An ulcerating PUVA keratosis on the lower leg.
reason the patient was treated with sodium fluoride 
(25 mg 3 times daily), 1,25-dihydroxyvitamin D5 
(O'lmg on alternate days), calcium Sandoz (1000mg 
a day) and aminohydroxypropylidene diphosphonate 
(50 mg three times a day). In November .1992, X-ray 
examination and ossal densometry were normal. There­
fore, treatment for osteoporosis was discontinued. It is
of cataract were due to the excessive use of topical
Discussion
Long-term PUVA therapy is a well established cause of
squamous ceil carcinomas, 
course of PUVA-induced malignancies has not been 
documented, to the best of our knowledge. It is, how-
carcmo-
the is permanent, and
ever, 
genesis
repeated UV exposures exert their biological 
according to a cumulative dose-response relation­
ship.1-4 Cyclosporin, as an immunosuppressive drug, 
decreases the immune surveillance of the skin and, 
hence, results in an increased occurrence of squamous 
cell carcinoma.12 In particular, during the treatment of
psoriatic plaques with PUVA and cyclosporin, multiple
i i . j j  ij ~ 11 carcinomas ----- -------------
In the
tinned to appear 
numbers.
case, squamous cell carcinomas
PlIVA treatment and con-
in high
long-term acitretin treatment, the
rtippearance
Figure 3. The histopathologica! appearance 
of a squamous cell carcinoma from the 
lower leg ( x 7 5 ).
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and, eventually, for a 4-year period, no new squamous 
cell carcinomas have been observed. Although it cannot 
be excluded with certainty that the appearance of new 
squamous cell carcinomas during cyclosporin treat­
ment resulted exclusively from PUVA therapy, the high 
frequency of tumours during cyclosporin therapy sug­
gests that cyclosporin, following PUVA treatment, con­
tributed to the induction of these carcinomas. It is a 
remote possibility that the cessation in the appearance 
of new squamous cell carcinomas is the result of a 
recovery in our patient’s immune status following the 
discontinuation of cyclosporin. On the other hand, a 
direct effect of acitretin on the development of squa­
mous cell carcinoma is more likely.
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